Article By:
Terry Chrisomalis
Friday, May 12, 2017 12:15 PM EST
Capricor Therapeutics reported an update on its phase 2 trial known as Allstar. It stated that the drug, CAP-1002 showed a low probability of achieving the primary endpoint of the study.
In this article: CAPR
